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Background: Anthrax is a zoonotic disease recognized to affect herbivores since Biblical times and has the widest
range of susceptible host species of any known pathogen. The ease with which the bacterium can be weaponized
and its recent deliberate use as an agent of terror, have highlighted the importance of gaining a deeper
understanding and effective countermeasures for this important pathogen. High quality sequence data has opened
the possibility of systematic dissection of how genes distributed on both the bacterial chromosome and associated
plasmids have made it such a successful pathogen. However, low transformation efficiency and relatively few
genetic tools for chromosomal manipulation have hampered full interrogation of its genome.
Results: Group II introns have been developed into an efficient tool for site-specific gene inactivation in several
organisms. We have adapted group II intron targeting technology for application in Bacillus anthracis and
generated vectors that permit gene inactivation through group II intron insertion. The vectors developed permit
screening for the desired insertion through PCR or direct selection of intron insertions using a selection scheme
that activates a kanamycin resistance marker upon successful intron insertion.
Conclusions: The design and vector construction described here provides a useful tool for high throughput
experimental interrogation of the Bacillus anthracis genome and will benefit efforts to develop improved vaccines
and therapeutics.Background
In 1876 Robert Koch ushered in microbial pathology by
establishing a causal relationship between Bacillus
anthracis microbes and the disease anthrax [1]. Distrib-
uted worldwide, Bacillus anthracis is a gram positive
bacterium capable of infecting the widest range of ani-
mals of any known pathogen [2]. The bacterium is nor-
mally found as an endospore in soil where a chance
encounter with an animal can permit entry through a
wound, food or inhalation leading to germination of the
spore into a vegetative bacterium. The vegetative phase
is relatively short consisting of only 20–40 generations.
The bacterium is believed to spend large periods of time
in spore form thus slowing evolutionary changes and* Correspondence: Thomas.Lamkin@wpafb.af.mil
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reproduction in any medium, provided the orexplaining the monomorphic nature of the bacterium
[3]. Human infection occurs most commonly through
accidental exposure to infected animals or animal prod-
ucts, such as hides or carcasses. 95% of infections occur
via the cutaneous route and more rarely through gastro-
intestinal and pulmonary routes [4,5]. The disease is dif-
ficult to diagnose because early symptoms are relatively
non-specific and, when left untreated without prompt
antibiotic intervention, can lead to fatality with rates
ranging from 20% for cutaneous exposure to as high as
100% for pulmonary anthrax. The high morbidity is due
to a rapid overwhelming of host defenses, fulminant
septicemia of vegetative cells and the action of bacterial
toxins expressed from vegetative cells. Once inside the
host, the spores are engulfed by macrophages where they
are transported to lymph nodes and germinate to
become vegetative cells that eventually disseminate
through blood and lymph causing septicemia and tox-
emia. The vegetative cells express three monomeric pro-
teins: protective antigen (PA), lethal factor (LF) andal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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virulence plasmid [6]. PA facilitates toxin entry by bind-
ing to receptors TEM8 and CMG2 on the surface of hu-
man and animal cells. Binding triggers PA cleavage
leading to formation of a heptameric or octameric pore
that binds and translocates EF and LF into the cytosol.
In binary complexes with PA, EF and LT are referred to
as edema toxin (ET) and lethal toxin (LT) respectively.
ET is an adenyl-cyclase that enhances cAMP production
and disrupts water homeostasis leading to kidney failure
and death. LT is a zinc protease that cleaves mitogen-
activated protein kinase kinases (MAPKK) and induces
pro-inflammatory cytokines and cellular apoptosis [4].
Antibodies predominantly directed against PA are the
basis of current vaccines that are used prophylactically [7].
The dramatic lethal consequences of an accidental
spore release at Sverdlovsk in the former Soviet Union
and the deliberate release of anthrax through letters in
the US in 2001 have renewed interest in neutralizing this
pathogen [8,9]. The complete sequence of Bacillus
anthracis and several of its close relatives is available
[10,11]. This potentially allows for systematic study of all
the genes contributing to the success of this important
pathogen. However, a complete dissection of Bacillus
anthracis is hampered by the difficulty of transforming
the bacteria (approximately 102-105 transformants per
μg DNA) and by relatively few simple ways to mani-
pulate the genome genetically [12-15]. Shatalin and
Neyfakh used a temperature sensitive (ts) plasmid to de-
liver a selectable marker flanked by upstream and down-
stream regions homologous to the gene to be disrupted
[14]. Through the manipulation of temperatures and
screening of antibiotic markers, a chromosomal inte-
grant could be obtained. Janes and Stibitz have created
an elegant set of plasmids to make markerless gene dis-
ruptions in two distinct steps [12]. In the first step, a
plasmid is constructed with an I-SceI site flanking a gen-
etic marker to be replaced and delivered on a ts replicon
using an erythromycin selection marker. On introduc-
tion of this plasmid in Bacillus anthracis, the plasmid
can integrate into the chromosome at the low frequency
of homologous recombination using the homology of
genomic sequences cloned into the plasmid. On shifting
to a restrictive temperature the plasmid is cured and it is
possible to select for those rare chromosomal integration
events. After appropriate steps to verify the success of
the first step, a second plasmid expressing I-SceI is in-
troduced. This leads to cleavage at the I-SceI site and
stimulating recombination via double strand break repair
which either leads to the desired recombination product
or restoration to the parental chromosomal configur-
ation. The desired product must be obtained through
physical screening of individual colonies. Finally, Leppla
and colleagues have exploited a selectable markerflanked by the loxP sites of the site-specific recombinase
Cre to leave a single loxP site at the site of marker inte-
gration which could then direct larger genome scale de-
letions through multiple rounds of loxP marker insertion
at distant sites and site-specific recombination between
them [13].
Many group II introns exhibit the ability to insert into
DNA through a now well understood series of biochem-
ical reactions [16]. The natural mobility of the Ll.LtrB
intron has been harnessed into a highly efficient gene
targeting technology to achieve gene disruption through
intron insertion in a number of gram positive and gram
negative bacterial hosts [17,18]. The ability to engineer a
group II intron to insert at desired genomic locations,
distinguishes group II introns from other insertional ele-
ments like transposons that either integrate randomly at
a low frequency or insert at a high frequency but only at
a specific genomic locus like the attTn7 site. Frequently,
the engineered group II introns insert at their newly pro-
gramed insertion sites in the genome at frequencies high
enough to be detectable by simple colony screening. The
high efficiency of insertion allows gene disruption with-
out the introduction of an antibiotic marker into the
chromosome and the efficient sequential creation of
multiple knockouts at disparate chromosomal sites. We
have adapted the Ll.LtrB intron insertion technology for
application to Bacillus anthracis and demonstrate the
remarkable simplicity with which gene inactivation
through intron insertion can be rapidly achieved.
Results and discussion
Group II intron based gene inactivation
Group II introns in general, and the Ll.LtrB group II in-
tron in particular, have been engineered into an efficient
gene disruption system [17,19,20]. We have adapted this
system for rapid gene inactivation in Bacillus anthracis.
Group II introns are autocatalytic RNA molecules [21].
Some group II introns exhibit a property of “homing”
where the intron recognizes the DNA equivalent of its
cognate exon junctions and inserts itself via retro-
transposition [16]. The biochemical basis of this intron
insertion has been deduced [22-24]. For example, the Ll.
LtrB intron interrupting a relaxase in Lactococcus lactis
is excised from its flanking exons through RNA catalysis
assisted by an intron encoded protein LtrA [25]. The
LtrA protein acts as a scaffold for efficient RNA directed
catalysis but also encodes a reverse transcriptase and
DNA endonuclease that are used for intron integration
into DNA targets [26]. The spliced Ll.LtrB intron re-
mains associated with LtrA to form a RNP particle. The
intron component of the RNP can recognize DNA exon
sequences resembling exon junctions through a combin-
ation of exon recognition elements (EBS1/δ and EBS2)
within the intron and DNA recognition preferences of
Saldanha et al. BMC Biotechnology 2013, 13:72 Page 3 of 8
http://www.biomedcentral.com/1472-6750/13/72the LtrA protein [27]. On encountering a suitable target,
the RNA component of the RNP can integrate through
reverse splicing of the intron RNA into the DNA target,
followed by an LtrA directed cleavage of the bottom
DNA strand which generates a primer that allows copy-
ing of the intron into DNA via the reverse transcriptase
activity of LtrA.
A vector permitting group II intron gene inactivation
using screening
To adapt group II introns for targeted gene disruption
in Bacillus anthracis we cloned the Ll.LtrB intron and
LtrA protein under the control of a cadmium inducible
promoter [28] using a gram positive/gram negative shut-
tle vector pRB373 as a backbone [29]. This vector offers
a pUB110 origin of replication for gram positives and a
ColE1 origin for gram negatives. The selection markers
are kanamycin/neomycin in gram positives and ampicil-
lin in gram negatives. For proof of principle, we changed
the sequences in EBS1/δ and EBS2 within the intron to
direct the intron to orf B of the IS605 insertion se-
quences which has 3 copies in the Bacillus anthracisA
C
Genomic
Intron insertion
Genomic
Intron insertion
M
Figure 1 Bacillus anthracis Targetron plasmid. (A) A variant of the Ll.Ltr
Bacillus anthracis was cloned into a Bacillus anthracis/E. coli. shuttle vector w
E. coli. The intron and intron encoded LtrA protein are driven from a Cadm
schematically as black bars in the intron) are sequences within the intron c
Reprogrammed sequences in EBS1/δ and EBS2 for efficient integration into
Bacillus anthracis Sterne via electroporation and selection for kanamycin re
flanking the potential site of intron insertion show virtually all colonies had
two lanes highlighted by a white arrow all three copies have an intron insegenome (located in ORF 1652, ORF 2876 and ORF
5071). Figure 1A shows general features of the vector
and the modified base pairing interactions within EBS1/
δ and EBS2 that allow the intron to recognize and insert
itself into IS605 orf B which are shown in Figure 1B.
The plasmid shown in Figure 1A was introduced into
Bacillus anthracis Sterne by electroporation and kana-
mycin resistant colonies were obtained. A single colony
was grown overnight and induced with 10 μM cadmium
for 90 minutes. Dilutions were plated on LB with-
out antibiotic selection and individual colonies were
screened for presence of the intron insertion using PCR
primers flanking the insertion site. Figure 1C shows that
this intron is remarkably efficient, and that every colony
screened yielded a PCR product consistent with intron
insertion into orf B of IS605. Direct sequencing of the
PCR product confirmed that the intron did successfully
integrate at the desired locus. Figure 1C also shows that
in most cases a PCR product that is consistent with an
intron free genomic product is also detectable, which
suggests that the intron has not integrated at all three
possible insertion sites. In two cases (highlighted by aB
Intron insertion
TargetronIS605 IS605
IS605
Genomic
E1 E2
Ll.ltrB
Cadmium Promoter
M
B group II intron designed to insert into orfB of IS605 elements of
ith a kanamycin resistance marker (bacillus) and ampicillin marker for
ium inducible promoter (Cd). (B) EBS1/δ and EBS2 (shown
ontrolling exon recognition via base pairing interactions.
IS605 are shown. (C) Plasmid IS605tt pRB373 was introduced into
sistant colonies. PCR screening of individual colonies using primers
an intron insertion. There are 3 genomic copies of IS605 and in the
rtion. Lanes marked M have 1 kb molecular weight markers.
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sistent with intron insertion in all three potential insertion
sites. The remarkable efficiency of this intron represents
the upper end of intron targeting efficiency [19]; i.e. 100%
insertion efficiency for all colonies screened with 1 in 24
colonies showing an intron insertion into three independ-
ent chromosomal insertion targets. For other targets we
have examined, the intron efficiency is considerably lower
requiring extensive arduous PCR screening to obtain a
single insertion.
A vector using genetic selection for detection of group II
intron gene insertion
To address the problem of finding intron insertions for
less efficient introns, we have engineered a vector with a
retrotransposition activated kanamycin resistance marker
that allows selection of intron insertion events [30].
Figure 2 illustrates the main features in this vector. An
erythromycin resistance marker was introduced into a
pRB373 shuttle vector. Group II intron expression was
driven using an Ntr promoter previously identified by
using a promoter trap strategy [31]. The kanamycin resist-
ance marker that is conditionally expressed only after in-
tron insertion was created by total DNA synthesis and
used codons optimized for low GC organisms. ThisGenome
M
M
Figure 2 Bacillus vector for selection of group II intron insertions. A s
group II intron based gene disruption. The plasmid is erythromycin resistan
coding sequence in an antisense orientation. Transcription of the group II i
generates a substrate that is capable of genomic integration at pre-determ
intron. Genomic integrants no longer have the td group I intron interruptin
kanamycin resistant. For PCR verification of intron insertion, primers (shown
flank the site of intron insertion in BAS4597 and BAS4553. kanamycin resist
plasmids reengineered to integrate the group II intron at BAS4597 and BAS
on a 1% agarose gel in TBE buffer and visualized by staining with ethidiummarker is expressed under its own promoter and is cloned
at a known neutral site in domain IV of the intron in an
antisense direction relative to the group II intron expres-
sion. A td self-splicing group I intron interrupts the kana-
mycin resistance coding sequences in the same orientation
as the Ll.LtrB group II intron. As a result of this configur-
ation, the kanamycin resistance marker in the donor plas-
mid is silent. Any leak-through expression from its own
promoter leads to a non-functional protein since the
group I intron interrupting it cannot be spliced out due to
its antisense orientation relative to kanamycin expression.
Group II intron RNA transcripts will, however, also have
the td intron autocatalytically removed restoring the con-
tinuity of the kanamycin coding sequence. If these tran-
scripts are used as substrates for site-specific intron
integration through reverse splicing into DNA targets and
reverse transcription, the kanamycin marker can then be
expressed. Thus successful retrotransposition events are
marked by a gain of kanamycin resistance which allows
for selection of rare intron integration events. As a proof
of principle, we have designed introns to insert at
BAS4553 (a methionine gamma-lyase) and BAS4597
(a pullulanase). The regions within the intron that interact
with DNA insertion sites were changed in order to direct
the intron to insert between nucleotides 343:344 of theBAS 4597
BAS 4553
Intron Insertion
Genomic
Intron Insertion
Genome
Kanr
Intron Insertion
chematic of the important vector features and selection scheme for
t but kanamycin sensitve because a td group I intron interrupts its
ntron from the Ntr promoter allows self- splicing of the td intron and
ined loci due to changes in sequences shown as black bars within the
g the kanamycin resistance gene and thus successful integrants are
as arrows above the genomic DNA schematic) were designed to
ant colonies arising in Bacillus anthracis Sterne after transformation of
4553 were screened by colony PCR and analyzed after electrophoresis
bromide. Lanes marked M have 1 Kb molecular weight markers.
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of the BAS4597 gene. The reengineered plasmid vectors
were introduced into Bacillus anthracis Sterne by
electroporation and selection on erythromycin plates.
Transformants were regrown in liquid media containing
erythromycin and plated on LB agar with kanamycin to
select for putative intron integration events. Kanamycin
resistant colonies were screened for successful intron
insertion by using PCR primers that flanked the site of in-
tron insertion. As can be seen in Figure 2, all kanamycin
resistant colonies for BAS4533 show a PCR product con-
sistent with group II intron insertion. For BAS4597, only
one of the 8 colonies is consistent with intron integration
at the desired site. The PCR products were sequenced and
indicate precise intron integration at the desired locus.
Conclusions
The vectors described here introduce a new tool for gen-
etic manipulation of Bacillus anthracis. The ability to
directly select for an insertional inactivation of a gene
using very few manipulations will accelerate our ability
to probe the role of the numerous uncharacterized genes
in the genome of this important pathogen and uncover
new targets for vaccination strategies or useful targets
for therapeutic intervention. While the vectors were de-
veloped and tested in Bacillus anthracis, the plasmid
backbone used to build the vector is derived from pUB110
a Staphylococcus aureus plasmid that has been extensively
used in Bacillus subtilis [29]. These vectors are therefore
likely to be able to be used across the Bacillus genus in-
cluding other members of the Bacillus cereus group such
as Bacillus cereus and Bacillus thuringiensis.
Methods
Bacterial strains and culture
E. coli strains: DH5α™ with genotype F– Φ80lacZΔM15
Δ(lacZYA-argF) U169 recA1 endA1 hsdR17 (rK–, mK+)
phoA supE44 λ– thi-1 gyrA96 relA1 and dam-dcm- (Life
Technologies) was used for routine cloning. Since trans-
formation efficiency of Bacillus anthracis is sensitive to
dam methylation [32], plasmid DNA for transformation
into Bacillus anthracis was prepared from a dam methyl-
ase deficient host E. coli (New England Biolabs C2925H)
with genotype: ara-14 leuB6 fhuA31 lacY1 tsx78 glnV44
galK2 galT22 mcrA dcm-6 hisG4 rfbD1 R(zgb210::Tn10)
TetS endA1 rspL136 (StrR) dam13::Tn9 (CamR) xylA-5
mtl-1 thi-1 mcrB1 hsdR2.
Bacillus anthracis (Sterne 34 F2) was obtained from
Colorado Serum Co. (Denver, CO).
Bacteria were grown in Luria-Bertaini (LB) broth or
Brain Heart Infusion (BHI). Antibiotics were added for
plasmid maintenance or selection at the following con-
centrations: ampicillin at 100 μg/mL; erythromycin at
400 μg/mL for E. coli and 4 μg/mL for Bacillus anthracisand kanamycin was used at 50 μg/mL for E. coli and
20 μg/mL for Bacillus anthracis.
Plasmid construction
The pRB373 plasmid was purchased from ATCC (cat.
no. 77373). The sequence of pRB373 is unpublished but
based on restriction enzyme digestion it contains a BsrG1
site. Because of this, a construct designed to retarget the
Ll.LtrB intron to insert within IS605 needed to be created
in three steps. In the first, a PCR fragment containing the
changes necessary to retarget the intron to IS605 was
digested with BsrGI and HindIII and cloned into the in-
tron donor plasmid pNL9161 of Staphylococcus aureus
digested with the same enzymes [33]. To optimize pairing
at the +1 site of the target, this intermediate plasmid was
modified by mutating C + 1 to G + 1. The resulting plas-
mid was then digested with SphI and SfoI, and the frag-
ment containing the Cd-inducible promoter, LtrB intron,
and LtrA protein was gel purified and cloned between the
SphI and SmaI sites of pRB373 to yield plasmid IS605-tt.
Preparation of plasmid DNA from E. coli, transform-
ation of E. coli, and recombinant DNA techniques were
carried out by standard procedures [34]. The plasmid
pRBEryNtr was constructed in several steps. In the first
step an erythromycin resistance marker was PCR ampli-
fied using pNL9162 as the template and oligonucleotide
primers SphI Ery 5’ GAATGAGGCATGCTACACCTCC
GGATA3’ and AgeI Ery 5’ GAT C ACCGGTCACACG
AA AAACAAGTTAAGGGATGCAG3’ using NEB PCR
mastermix. This yielded a 1.2 Kb fragment which was
then purified and digested with SphI and AgeI. It was
then cloned into pRB373 (which had been digested with
the same enzymes) to yield pRB373Ery. The potent Ba-
cillus Ntr promoter identified by Gat et al., [31] was
amplified from Bacillus anthracis Sterne genomic DNA
using PCR primers 5’ SphI Nitro 5’ GatC GCATGC
CTGAGTTGGATCATCATTATATGAAAGGC3’ and 3’
Nitro HindIII XhoI EcoRI 5’Gatc gaattc ctcgag gag
AAGCTTTTTTTCA TATGTATAC ATC ATA TTC
TGC C3’. The PCR product was digested with SphI and
EcoR1 then cloned into pRB373Ery digested with the
same enzymes to yield pRB373 EryNtr. The coding se-
quence of a select agent compliant kanamycin allele was
optimized for expression in low GC organisms and synthe-
sized (Genscript, Piscataway, NJ). The synthetic fragment
also included a self-splicing td intron in the antisense
orientation inserted between codons 15 and 16 of the
kanamycin gene and cloned into pRB373. A HindIII-XhoI
fragment with the group II intron Targetron was cloned
into pRB373 digested with the same enzymes. Finally, PCR
mutagenesis was used to generate the mutations necessary
to retarget the intron to BAS4597 & BAS4553 and in-
troduced as HindIII-BsrG1 fragments into the vector as
described above.
Table 1 Targetron insertion sites and scores
Gene insertion site -30 to -1 NT upstream LtrB intron +1 to +15 NT downstream Score
IS605 435|436 s CCGATTATAGATCATCAAAAATATAGTGTA gtgc…tcac GAAATTATTCGCAAA 9.3
BAS4553 343|344 s GTTCAAATGGATTATACGGATGCACGTACG gtgc…tcac GCTTTTTGGAAGTGT 8.4
BAS4597 1794|1795 s AATCAATTAGATTGGGATCGAAAAGAGAAA gtgc…tcac GAAATAGAGACCGTT 7.3
The gene chosen for intron insertion is shown in the first column with the nucleotide positions at which the intron is designed to insert at within the gene shown
beside the gene name. All intron insertions are in the sense orientation relative to gene transcription and designated here with the suffix “s”. The sequence of
30 nucleotides upstream and 15 nucleotides downstream of the intron insertion site are shown together with a numeric score reflecting expected efficiency
based on a learning set of Ll.Ltrb intron insertions.
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retargeting
The sequence of Bacillus anthracis genomic DNA to be
targeted for disruption was scanned for potential intron
insertion sites using a computer algorithm derived from
a learning set of successful intron integrations [19]. The
resulting insertion sites are shown in Table 1 and the
mutations necessary to retarget the intron to a desired
site were introduced through PCR mutagenesis using
two pairs of partially overlapping primers (Table 2) to
assemble a short DNA fragment flanked by HindIII and
BsrG1 sites and incorporating the changes within the in-
tron required to redirect the intron to a new locus as de-
scribed previously [17]. Briefly, for each mutant intron
to be created 10 cycles of PCR was performed using
2 μL of the mutant specific IBS and EBS universal pri-
mer at a concentration of 100 μM and 10 μM respect-
ively in a 20 uL reaction using Phusion® (NEB) PCR
mastermix and 0.2 ng of wild-type intron template. In a
separate tube a similar reaction was performed using
mutant specific primers EBS1delta (100 μM) and EBS2
(10 μM) primers. At the end of the first round of asym-
metric PCR, the two reactions were combined and
allowed to proceed through 20 more PCR amplification
cycles. The resulting PCR products incorporating all
necessary mutations were gel purified, digested withTable 2 Primers used for retargeting
Primer name Primer se
IS605-435|436 s AAAAAAGCTTATAATTATCCTTAAAATA
IS605-435|436 s CAGATTGTACAAATGTGGTGATAACAGATA
IS605-435|436 s TGAACGCAAGTTTCTAATTTCGGTT
BAS4553-343|344 s AAAAAAGCTTATAATTATCCTTAGATGC
BAS4553-343|344 s CAGATTGTACAAATGTGGTGATAACAGATA
BAS4553-343|344 s TGAACGCAAGTTTCTAATTTCGATTG
BAS4597-1794|1795 s AAAAAAGCTTATAATTATCCTTACGAAA
BAS4597-1794|1795 s CAGATTGTACAAATGTGGTGATAACAGATA
BAS4597-1794|1795 s TGAACGCAAGTTTCTAATTTCGGTT
EBS-Universal AACCGAAATTAGA
The primers shown were used in PCR to generate a HindIII BsrG1 fragment that wa
location indicated in the primer name. The exact nucleotide the intron is designed
primer sequences.HindIII and BsrG1 and cloned into the intron donor
plasmids described above cut with the same enzymes.
Bacillus anthracis genomic DNA isolation
Bacillus anthracis was grown overnight and 2 mL were
harvested for genomic isolation with the Epicentre Bio-
technologies DNA & RNA purification kit (cat. no.
MC85200). Final yield was 70 μL at ~1.3 mg/mL.
Bacillus anthracis electroporation
Electroporation conditions described in Koehler et al.
were followed with a few modifications [35]. A culture
of Bacillus anthracis Sterne was grown overnight in
BHI. The following day, 1 mL of the overnight culture
was used to inoculate 100 mL of BHI supplemented with
0.5% glycerol in a 1000 mL baffled Erlenmeyer flask and
incubated at 37°C with shaking at 225 rpm until the cul-
ture reached an OD600 of ~ 0.6. At this point the culture
was chilled on an ice bath and filtered through a filter
assembly pre chilled to 4°C and washed with an ice cold
electroporation buffer containing 10 mM Hepes pH 7.0
and 10% Glycerol (3×50 mL washes). The washed bac-
teria were resuspended from the filter using 10 mL of
ice cold electroporation buffer, then aliquoted and flash
frozen. Aliquots of electrocompetent Bacillus anthracis
(Sterne) were electroporated with 3 μg of dam-dcm-quence Pairings changed
CAGTGTAGTGCGCCCAGATAGGGTG IBS1/2
AGTCAGTGTAGATAACTTACCTTTCTTTGT EBS1/δ
TATTTCCGATAGAGGAAAGTGTCT EBS2
CCGTACGGTGCGCCCAGATAGGGTG IBS1/2
AGTCCGTACGGCTAACTTACCTTTCTTTGT EBS1/δ
CATCTCGATAGAGGAAAGTGTCT EBS2
CGAGAAAGTGCGCCCAGATAGGGTG IBS1/2
AGTCGAGAAAGATAACTTACCTTTCTTTGT EBS1/δ
TTTCGTCGATAGAGGAAAGTGTCT EBS2
AACTTGCGTTCA None
s exchanged into the Targetron vectors and retarget the intron to the genomic
to insert at is designated by a | at the genomic location indicated above the
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was conducted on a BioRad Gene Pulser. Electropor-
ation conditions were as follows: 2,500 V, 25 μF, 400Ω.
The time constant for the pulse was (on average) 6.5 ms.
After electroporation, the cells were diluted with 1 mL
of BHI augmented with 10% glycerol, 0.4% glucose and
10 mM MgCl2. The cells were incubated for one hour
before plating on LB or BHI agar plates with 20 μg/mL
kanamycin or 4 μg/mL erythromycin.
Generation of targetron insertions
A frozen glycerol stock of Bacillus anthracis Sterne
transformed with the plasmid vector designed to insert
into IS605 was used to inoculate LB augmented with
20 μg/mL kanamycin and shaken at 220 RPM at 37°C
overnight. The overnight cultures were used to prepare
fresh dilutions by inoculating 100 μL of the overnight
culture into 25 mL LB augmented with 20 mg/mL kana-
mycin and shaken (220 RPM) at 37°C. When the cul-
tures reached an OD600 of 0.6, 25 μL of 10 mM CdCl2
was added in order to induce the cadmium promoter
controlling expression of the targetron. Cultures were
induced for 90 min. Serial dilutions of the induced cul-
tures were prepared and 100 μL aliquots taken from the
10-4 and 10-5 dilutions were plated on LB agar without
antibiotic selection. Single colonies were tested for in-
tron insertion via colony PCR using primers flanking the
site of intron insertion. A frozen glycerol stock of Bacil-
lus anthracis Sterne transformed with the plasmid vector
designed to insert into BAS4597 or BAS4553 was used
to inoculate LB augmented with 4 μg/mL erythromycin
and shaken at 220 RPM at 37°C overnight. The overnight
cultures were used to prepare fresh dilutions by ino-
culating 100 μL into 25 mL LB with 4 μg/mL erythro-
mycin and shaken (220 RPM) at 37°C and grown to
saturation. 0.2-0.5 mL of the saturated cultures was spread
on LB agar plates containing kanamycin at 20 μg/mL and
incubated at 37°C for three days. Any kanamycin resistant
colony arising reflects a potential intron insertion and this
was verified by colony PCR using primers flanking the site
of intron insertion.
Colony PCR screening
Colonies were assessed for potential intron insertions by
conventional PCR. Specific primers flanking the site of
chromosomal insertion were designed and synthesized
by Integrated DNA Technologies. DNA was amplified
using 1 μL of LongAmp Taq DNA Polymerase (New
England Biolabs), 2.5 μL of 5× LongAmp Taq Reaction
Buffer, 0.4 μL of 10 mM dNTP Mix (New England
Biolabs), nuclease-free water (Ambion), 200 nM of each
primer and whole cell template in a final volume of
12.5 μL per reaction. The following cycling conditions
were used: initial denaturation at 94°C for 30 sec,followed by 30 cycles of denaturation at 94°C for 30 sec,
annealing at 60°C for 45 sec and extension at 65°C for
3 min, with a final extension at 65°C for 10 min. Prod-
ucts were visualized using 1% ethidium bromide (Fisher
Bioreagents) on a 1% agarose gel.
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